Regulatory T cells (Treg) 
Introduction
Naturally occurring regulatory T cells (nTreg) are produced in the thymus during normal T cell development [1] and are involved in the maintenance of self-tolerance [2-5] and development of tolerance to allogeneic transplants [6] [7] [8] . Despite its broad spectrum of reactivity, the frequency of nTreg responding to foreign antigens is low and unable to provide protection against grafts mismatched for multiple major and minor histocompatibility antigens following transplantation [9, 10] . On the contrary, Treg induced in response to antigen (iTreg) are generated from naive T cells under defined conditions in vivo and in vitro [2, [11] [12] [13] [14] [15] [16] [17] [18] [19] . For therapeutic purposes, it may be possible to harness both the potential of nTreg as well as to generate T cells with regulatory activity to defined antigens, such as alloantigens, ex vivo. Repeated stimulation of unfractionated CD4 + cells in the presence of IL-10 or using a combination of immunosuppressive drugs induces the selection of Treg in vitro. These induced Treg are able to prevent colitis or central nervous system inflammation in animal models [20] [21] [22] . Pre-treatment of naive CBA mice with a non-depleting anti-CD4 mAb (YTS 177) and donor-specific (B10) transfusion enables the development of alloantigen-reactive CD4 + Treg, which render the recipient tolerant to a subsequent challenge with an allogeneic cardiac allograft [16, [23] [24] [25] . The transplant provides a source of donor alloantigen indispensable for the persistence of the regulatory cells in vivo [26] . In this study, we have addressed whether a similar strategy can be used in vitro to select and expand CD4 + Treg. We show that alloantigen stimulation of total CD4 + or CD25 -CD4 + naive cells in the presence of a non-depleting anti-CD4 antibody (YTS177) drives the selection of a population of Treg that express CD25, CD62L, CCR7 and Foxp3 and are capable of suppressing the proliferation and cytokine expression of naive responder T cells, in vitro. Most importantly, these Treg are able to prevent the rejection of an allogeneic skin graft mediated by CD45RB high CD4 + cells when co-transferred into CBA.Rag -/-recipients. Interestingly, expansion of the in vitro selected CD4 + cells with regulatory activity in the presence of IL-2 resulted in a loss of their capacity to prevent allograft rejection in vivo, although they retained their suppressive properties in vitro. This in vitro approach provides a complementary strategy to in vivo selection of Treg for controlling rejection and illustrates the tolerogenic potential of non-depleting anti-CD4 antibodies.
Results
Alloantigen stimulation in the presence of anti-CD4 antibody selects CD4 + cells with regulatory properties in vitro and in vivo
Here, we asked whether in vitro blockade of CD4 signals to T cells at the time of alloantigen recognition, i.e. in the presence of allogeneic APC, would result in the selection of a population of CD4 + cells with suppressive properties. Purified, unfractionated CD4 + cells from naive CBA mice were cultured with irradiated, allogeneic splenocytes from B10 mice in the presence of 5 lg/mL anti-CD4. After 8 days in culture, their suppressive properties were investigated by coculturing the cells with naive, syngeneic CD4 + cells in the presence of allogeneic B10 splenocytes. As illustrated in Fig. 1A (Fig. 3A ). Therefore, we tested whether the population of CD4 pres could be expanded. After 8 days in culture with anti-CD4, CD4 + cells were restimulated with allogeneic splenocytes (B10) for a further 7 days in the presence of exogenous IL-2 (25 U/mL). Indeed, the addition of IL-2 resulted in an eightfold increase in the number of cells recovered from the cultures and the potential of the expanded CD4 pres to prevent proliferation of naive CD4 + cells in vitro was not diminished (Fig. 3B) . Furthermore, suppression was still as potent at very low ratios such as 1:50 (8.3% proliferation at 1:50 vs. 9.1% at 1:1, Fig. 3B ). In contrast to the non-expanded anti-CD4 Treg, as few as 4000 expanded CD4 pres were now sufficient to prevent proliferation of naive CD4 + cells.
Next, we investigated whether the expanded CD4 pres were able to prevent skin graft rejection in vivo. All mice reconstituted with CD45RB high CD4 + cells alone rejected their skin grafts acutely grafts (n = 8, MST = 14 days, Fig. 3C ). Co-transfer of expanded CD4 pres could not prevent skin graft rejection although rejection occurred with a delayed kinetic (n = 8, MST = 11 days, p>0.05, Fig. 3C ). These results indicate that although the expanded CD4 pres show a high regulatory potential in vitro, they were unable to prevent skin graft rejection in vivo.
Cells with highest regulatory potential are present within the CD62L + CD25 + CD4 + subpopulation
Lymphocyte extravasation from the blood circulation into high endothelial venules and subsequent entry into the secondary lymphoid organs involves a series of step-wise events, which involve CD62L and CCR7 [32] . The mAb, which block the interaction of CD62L with its ligands, prevent indefinite allograft survival and highlight the importance of this molecule for alloantigen tolerance [33] . To understand the differences in regulatory potential in vivo between expanded and non-expanded CD4 pres , the profile of cell-surface expression of both T cell populations was analysed. Cells were harvested after 8 days in culture (non-expanded CD4 pres ) or after a further 7 days in culture in the presence of IL-2 (expanded CD4 pres ) and stained with antibodies recognising CD62L and CD25. Of all non-expanded CD4 pres , 36% expressed both CD25 and CD62L, whereas only 11% of the expanded population could be stained with both antibodies (Fig. 4A ). These findings together with published studies from other groups [34-37] prompted us to investigate if this difference in CD62L expression could explain the results obtained in vivo ( Fig. 1C and 3C (Fig. 5B) , irrespective of previous culture in the presence (n = 5, MST = 5 CD4 pres prevented rejection in four out of six mice receiving B10 skin grafts (*, n = 6) whereas none of the BALB/c skin grafts were accepted (*, n = 7). Results were pooled from two independent experiments. accordance with the regulatory potential found in vivo for each of these cell populations (Fig. 5B) 
Discussion
Based on an established in vivo protocol known to select alloantigen-reactive CD25 + CD4 + regulatory T cells in vivo [16, 23], we investigated whether a similar strategy would result in the selection of T cells with regulatory potential in vitro. Such an in vitro approach is attractive, as the ex vivo generated regulatory cells could be used throughout the post-transplant course to enhance or sustain the unresponsive state achieved by the in vivo therapy. In this system, mouse CD4 + cells were purified and cultured for 8 days with alloantigen in the form of allogeneic APC and in the presence of a non-depleting anti-CD4 mAb. This in vitro combination led to the selection, of CD4 + cells, designated CD4 pres , secreting high amounts of IL-10 and IFN-c (data not shown) that are able to suppress the proliferation of naive syngeneic T cells (Fig. 1A) . More importantly, CD4 pres are able to prevent rejection mediated by co-transfer of naive T cells (Fig. 1B  and C they completely lost regulatory capacity in vivo (Fig. 3B and C) . This loss of functional activity in vivo may result from the dramatic decrease in the percentage of cells co-expressing CD25 and CD62L and functional changes of the CD62L -
CD25
int CD4 + population after expansion with IL-2 (Fig. 4A) The ultimate challenge for our in vitro generation protocol would be to test the regulatory capacity of CD4 pres cells upon transfer into fully immunocompetent recipients. Indeed, we are currently performing experiments in which we transfer CD4 pres cells into otherwise untreated naïve C57BL/6 mice receiving an allograft. . MR mice acutely reject B10 skin grafts (&, n = 6; MST = 16.5 AE 3.5 days). Co-transfer of 2 Â 10 5 CD4 pres prolonged skin graft survival (*, n = 5; MST = 24.8 AE 3.9 days) whereas co-transfer of 2 Â 10 5 CD4 abs resulted in accelerated rejection (~, n = 3; MST = 13.0 AE 0.0 days).
In situations characterised by high responder frequencies such as stringent strain combinations and most likely in clinical transplantation we need powerful protocols for in vitro generation and differentiation of antigen specific regulatory T cells. Our protocol presented here may be one approach to generate such potent Tregs.
Recently, Golshayan et al. [44] Treg could not inhibit direct pathway alloresponses, such that C57BL/6 skin transplants were rejected with the same kinetic as in control mice [44] . These data indicate that Treg with a broader spectrum of alloreactivty is most likely required to control rejection of a fully allogeneic graft. The protocol for generating Treg reported here is aimed at selecting Treg controlling direct pathway immune responses and therefore complements the findings made by Golshayan et al. [44] . The underlying mechanism by which anti-CD4 antibody treatment induces the enrichment/selection of Treg in vitro remains to be investigated. CD4 is an important accessory and costimulatory molecule that augments the signal received by the TCR complex and helps in the activation of the T cells [45] . Blockade of this interaction using anti-CD4 antibodies increases the threshold of activation through the TCR, so that, under these conditions, only cells with high affinity have the capacity to be activated and proliferate [46] . These cells with high affinity/ specificity TCR could be identical with cells that manifest regulatory activity in this study. Indeed, autoreactive CD25 + CD4 + regulatory cells can be generated in the thymus by interactions with a single self-peptide. Selection of these cells appears to require a TCR with high affinity for a self peptide as thymocytes with low-affinity TCR do not undergo selection into this pathway [47] . Furthermore, reduced or blocking levels of CD4 expression, can convert T cell responses from stimulatory to inhibitory [48] . We can speculate that using the protocol described here, T cell activation has purposefully become more difficult and only a small percentage of cells can undergo activation and proliferation (regulatory population), while cells that do not receive any signals eventually die by apoptosis (these include the effector population). Indeed, in our previous studies we could show that anti-CD4 mAb-treated allo-reactive T cells are characterised by a relative resistance to activation-induced cell death (AICD) [49] . Thus, we can conclude that anti-CD4 mAb treatment of allo-reactive T cells facilitates the expansion and differentiation of antigen.specific Treg, which are characterised by a relative resistance to AICD, whereas effector T cells dye by apoptosis. Alternatively, the anti-CD4 antibody may directly deliver a negative signal into the T cells [50] and thereby drive the selection of a population of Treg instead of selecting it from a pre-existing pool. Interestingly, a recent study performed by McFadden et al. [51] has revealed that stimulation with the CD4 ligand IL-16 results in enhanced migration and de novo induction of a regulatory population of CD25
+ cells. It is likely that TCR affinity and CD4 expression levels at the cell surface both play equal roles in our protocol. Following this line of thinking, we believe that it may be possible to develop protocols, targeting one or more accessory or costimulatory molecules [11] , to generate stringent culture conditions in which only a specific T cell population (regulatory population) can be selected [20] . Our findings may help to understand the mechanisms underlying the function of Treg in vitro and in vivo, which will enable its use the cells for therapeutic strategies in vivo. This protocol, stimulating T cells with alloantigen-presenting cells in the presence of anti-CD4, provides a powerful, simple and fast method of obtaining cells ex vivo with strong regulatory potential but also illustrates the immense tolerogenic and therapeutic potential of non-depleting anti-CD4 antibodies. 
Reagents and monoclonal antibodies
The following reagents were used for in vitro assays and flow cytometry. The hybridomas YTS 169.4.2 (anti-CD8) and YTS 177.9 ("YTS 177", anti-CD4) were kindly provided by Professor Herman Waldmann (Sir William Dunn School of Pathology, Oxford, UK). TIB120 (anti-class II) was obtained from American Type Culture Collection (ATCC) Manassas, VA). RM4-5 (anti-CD4)-cychrome, 16A (anti-CD45RB)-PE, MEL-14 (anti-CD62L)-PE, 7D4 (anti-CD25)-biotin and streptavidin-allophycocyanin were from PharMingen (San Diego, CA). 4B12 (anti-CCR7)-PE and FJK-16s (antiFoxP3)-APC were from eBioscience (San Diego, CA). CFSE was from Molecular Probes (OR).
Cell preparation and purification

Purification of T cell subpopulations
Single-cell suspensions from spleen and lymph nodes of naive CBA mice were prepared by forcing the organs through a 70-lm nylon mesh. After erythrocyte removal by hypotonic lysis, cell suspensions were incubated with YTS169 (anti-CD8, 200 lg/mL) and TIB120 (anti-class II, 100 lg/mL) at 2 Â 10 8 cells/mL. Cell suspension was incubated with sheep anti-rat-coated Dynabeads Cell culture RPMI 1640 culture medium was supplemented with 10% FBS, 2 mM L-Glutamine, 0.5 mM 2-mercaptoethanol, and 100 U/mL each penicillin, streptomycin and kanamycin. Irradiated (3600 rad) allogeneic total splenocytes from B10 mice were used as APC (B10 APC). purified from naive CBA mice were used routinely to elicit rejection of an allogeneic skin graft [16] . The day after reconstitution, all mice received a B10 skin graft as previously described [16] . Graft rejection was defined as complete destruction of the skin graft.
Flow cytometric analysis
Cell cultures were incubated with the appropriate antibodies. All incubations were carried out for 20 min at 4 C. Data were acquired using a FACSort (Becton Dickinson, San Jose, CA) and analysed using CellQuest software package (Becton Dickinson). Intracellular staining for FoxP3 studies was performed according to the manufacturer's instructions.
Statistics
The Log Rank Method was used to compare allograft survival between groups using GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, CA).
The data were analysed using a two-tailed unpaired Student's t-test. Results are given as the mean AE SD. p-values of <0.05 were considered significant.
